Synthetic Control Subjects for Alzheimer's Disease Clinical Trials (JSM 2019)

Objective: To develop a method to model disease progression that simulates detailed clinical data records for subjects in the control arms of Alzheimer's disease clinical trials.Methods: We used a robust data processing framework to build a dataset from a database of subjects in the control arms of a diverse set of 28 clinical trials on Alzheimer's disease. From this dataset, we selected 1908 subjects with 18-month trajectories of 44 variables and trained a probabilistic generative model called a Conditional Restricted Boltzmann Machine (CRBM) to simulate disease progression in 3-month intervals across all variables. Results: Based on a statistical analysis comparing data from actual and simulated subjects, the model generates accurate subject-level distributions across variables and through time. Focusing on a common clinical trial endpoint for Alzheimer's disease (ADAS-Cog), we show the model can accurately predict disease progression and may be used to model the control arm of a clinical trial whose data are distinct from the training and test datasets. Conclusion: The ability to simulate dozens of clinical characteristics simultaneously is a powerful tool to model disease progression. Such models have useful applications for clinical trials, from analyzing control groups to supplementing actual subject data in control arms.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Digital Twins: A Tool for Risk Mitigation in the Era of COVID-19

Blog

CB Insights 2020 Digital Health 150: Unlearn.AI named in List of Most Innovative Digital Health Startups

Blog

Embracing Innovation to Move Forward

At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.
Unlearn is thrilled to be recognized as a contributing member of the international community of pioneers in health.
In what ways can we mitigate risk and apply innovative solutions to unstable trials in the wake of COVID-19?